Although cluster of differentiation (CD)8+ regulatory T (Treg) cells have been in the last 20 years more studied since evidences of their role in tolerance as been demonstrated in transplantation, autoimmune diseases and cancer, their characteristics are still controversial. In this review, we will focus on recent advances on CD8+ Treg cells and description of a role for CD8+ Treg cells in tolerance in both solid organ transplantation and graft-versus-host disease and their potential for clinical trials.
An expert review on the controversial FoxP3-CD8+ and FoxP3+CD8+ Tregs, their immunobiology, potential role in tolerance, and their potential for clinical trials in solid organ transplantation and GvHD.
1 Centre de Recherche en Transplantation et Immunologie, INSERM, Université de Nantes, Nantes, France.
2 Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
3 LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France.
Received 15 February 2018. Revision received 29 March 2018.
Accepted 17 April 2018.
The Labex IGO program supported by the National Research Agency via the investment of the future program ANR-11-LABX-0016-01 and the IHU-Cesti project program ANR-10-IBHU-005 is acknowledged. The IHU-Cesti project is also supported by Nantes Metropole and the Pays de la Loire Region.
The authors declare no conflict of interest.
C.G. participated in the writing of the article. I.A. participated in the writing of the article. S.B. participated in the writing of the article.
Correspondence: Carole Guillonneau, PhD, Centre de Recherche en Transplantation et Immunologie INSERM 1064-ITUN, 30 Bd. Jean Monnet, 44093, Nantes Cedex 01, France. (firstname.lastname@example.org); Ignacio Anegon, MD, Centre de Recherche en Transplantation et Immunologie INSERM 1064-ITUN, 30 Bd. Jean Monnet, 44093, Nantes Cedex 01, France. (email@example.com).